Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer

Prostate

Volumn 45, Issue 3, 2000, Pages 216-224

  Strohmeyer, Dagmar ^a,b,c   Rssing, Christian ^b   Bauerfeind, Anja ^c   Kaufmann, Olaf ^b   Schlechte, Horst ^b   Bartsch, Georg ^a   Loening, Stefan ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Technische Fachhochschule ^*  (Germany)

Author keywords

Angiogenesis; p53; Progression; Prostate cancer; VEGF

Indexed keywords

POLYCLONAL ANTIBODY; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION FUNCTION; DENSITY; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION;

ADULT; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHOKINES; MALE; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033767659     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C     Document Type: Article

References (57)

1. Establishing a link between oncogenes and tumor angiogenesis
2. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
3. Vascular endothelial growth factor (VEGF) and its receptors
4. Signaling angiogenesis and lymphangiogenesis
5. Molecular angiogenesis
6. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder
7. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinoma of the gastrointestinal tract
8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
9. Expression of vascular endothelial growth factor and its receptor flt and KDR in ovarian cancer
10. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
11. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
12. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a preclinical model
13. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumors in vivo
14. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
15. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
16. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
17. Quantitative microvessel density. A staging and prognostic marker in human prostatic carcinoma
18. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
19. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
20. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy
21. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study
22. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
23. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
24. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5 to 7 adenocarcinoma
25. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
26. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis
27. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer
28. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
29. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia
30. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells
31. The TMN classification of prostate cancer
32. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
33. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma
34. Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: A comparison with SSCP analysis
35. p53 Tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer
36. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - Investigation by temperature gradient gel electrophoresis (TGGE)
37. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor
38. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice
39. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
40. Angiogenic peptides in prostatic disease
41. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: An in vitro model for assessment
42. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
43. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression
44. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium
45. Activated ras alleles in human carcinoma of the prostate are rare
46. Infrequent RAS oncogene mutations in human prostate cancer
47. Comparison of ras activation in prostate carcinoma in Japanese and American men
48. Mutations of ras genes are relatively frequent in Japanese prostate cancers: Pointing to genetic differences between populations
49. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
50. p53 Nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy
51. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer
52. Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression
53. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors
54. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy
55. An uncertain role for p53 gene alterations in human prostate cancers
56. p53 Protein and gene alterations in pathological stage C prostate carcinoma